Answers are grounded in this paper and cite their sources.
Antibodies are widely used as molecular recognition elements in biosensors because of their high affinity, specificity, and versatility. However, their performance may require further optimization when detecting low-abundance targets, structurally related compounds, or analytes in complex sample matrices. In recent years, in vitro directed evolution has provided a complementary approach to antibody engineering by enabling controlled sequence diversification and selection under application-relevant conditions. This review summarizes recent advances in the in vitro directed evolution of antibodies for biosensing applications. Major engineering strategies are discussed, including random diversification and recombination, semi-rational and focused mutagenesis, structure- and sequence-based design, and AI-assisted optimization. The influence of antibody formats, including full-length antibodies, Fab fragments, single-chain variable fragments (scFvs), and nanobodies, on library construction, selection, and molecular recognition is also examined. Furthermore, strategies for evolving antibodies against small molecules, peptides, and protein antigens are reviewed, highlighting how antigen properties influence the design of diversification and selection approaches. Representative applications in food safety, environmental monitoring, and biomedical diagnosis are evaluated, with attention to antibody-level improvements and their translation into biosensor performance. Finally, current limitations and future opportunities are discussed, particularly in relation to screening efficiency, reproducibility, application-oriented evaluation, and the integration of computational methods and advanced biosensing platforms.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: